Goldman Sachs raised the firm’s price target on Kestra Medical (KMTS) to $27 from $25 and keeps a Neutral rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- Kestra Medical price target raised to $25 from $22 at Goldman Sachs
- Kestra Medical Technologies Reports Strong Earnings Growth
- Kestra Medical price target raised to $30 from $28 at Stifel
- Morning Movers: Cannabis stocks higher after reports of reclassification
- Kestra Medical price target raised to $28 from $27 at Wells Fargo